Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults

Summary

Emerging adults are a particularly vulnerable group for experiencing the immediate and potentially lifelong negative impacts of habitual cannabis use, and trends suggest that cannabis use disorder (CUD) will soon escalate in this population. The proposed research will combine clinical pharmacology, non-invasive brain stimulation, and neuroimaging techniques to establish the brain mechanisms of cannabinoid-impaired decision-making processes in emerging adults with CUD. Results from this project will inform CUD prevention/treatment efforts in this high-risk group and address a growing public health concern.

Conditions

• Neurosciences
• Substance-Related Disorders
• Behavior Problem

Interventions

DEVICE

Placebo TMS Sham

Individuals will receive placebo dose and sham TMS.

DRUG

Marinol 10Mg Capsule TMS Sham

Individuals will receive 10mg dose and sham TMS.

DRUG

Marinol 30Mg Capsule TMS Sham

Individuals will receive 30mg dose and sham TMS.

DEVICE

Placebo TMS Real

Individuals will receive placebo and real TMS.

OTHER

Marinol 10Mg Capsule TMS Real

Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

OTHER

Marinol 30Mg Capsule TMS Real

Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Michael J. Wesley, PhD

  lead OTHER

Principal Investigators

• Michael J Wesley, PhD · University of Kentucky

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

34 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-07-15

Primary Completion

2023-12-13

Completion

2023-12-13

FDA Drug

Yes

FDA Device

Yes

Countries

• United States

Study Locations